Rachel Martini

1 month ago | cell.com | Melissa Davis |Rachel Martini

Main textCurrent precision medicine approaches often fail to account for genetic ancestry, leading to disparities in diagnosis, treatment response, and outcomes. The performance and interpretation of precision oncology tools, including next-generation sequencing panels, liquid biopsies, and other genomic assays, can vary significantly across patient populations with diverse genetic ancestries.

Mar 6, 2024 | jamanetwork.com | Lisa Newman |Rachel Martini |Sandra Demaria |Silvia C. Formenti

Population-based breast cancer mortality rates are 40% higher in Black women than White women.1 This disparity is partly explained by Black women having a 2-fold higher incidence of tumors negative for expression of estrogen receptor, progesterone receptor, and ERBB2, ie, triple-negative breast cancer (TNBC).1 Advances in cancer genomics have generated insights regarding immunotherapeutics in breast cancer.